Regeneron and Telix Pharmaceuticals Sign US$4.3 B Radiopharmaceutical Oncology Deal

By Hitesh Udar

Pharma Deals Review: Vol 2026 Issue 4 (Table of Contents)

Published: 30 Apr-2026

DOI: 10.3833/pdr.v2026.i4.3011     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Regeneron and Telix Pharmaceuticals have entered into a strategic collaboration to jointly develop and commercialise next-generation targeted radiopharmaceutical therapies for solid tumours...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details